多西他赛联合FOLFOX6对晚期胃癌疗效观察

摘要

Objective:To evaluate the efficacy and side-effect of Docetaxel combined with FOLFOX6 in treatment of advanced gastric cancer. Method:36 patients received intravenous Docetaxel 75 mg/m2 (ivgtt at d 1)with FOLFOX6(oxaliplatin 85 mg/m2,d 1,CF 200 mg/m2,Ⅳ,d 1、2,5-FU 400 mg/m2,iv,d 1,2,5-FU 2400 mg/m2,CIV,46 h,the regimen were repeated every 21 days.Result:36 patients were evaluated for response. The overall clinical response rate was 58.3%(21/36).The time to progression was 5.5 months.Median One year survival rate was 46.5%and 59.5%cases acquired improved life quality.The major toxicity included degree bone marrow inhibition(69.4%),neurological toxicity(55.6%).The most areⅠ-Ⅱdegree toxicity.Conclusion:The combination of Docetaxel and FOLFOX6 is an effective therapy for the patients with advanced gastric cancer and mild toxicity for patients with advanced gastric cancer.%　　目的：评价多西他赛联合FOLFOX6方案治疗晚期胃癌的疗效及毒副反应.方法：对无法手术的36例Ⅲ~Ⅳ期胃癌患者,应用多西他赛75 mg/m2,d 1,奥沙利铂(85 mg/m2,d 1),亚叶酸钙(200 mg/m2,静脉注射,d 1)、2,5-FU 400 mg/m2,静脉注射,d 1、2,5-FU 2400 mg/m2,CIV,46 h,21 d为1个周期.结果：有效率58.3%(21/36),中位TTP时间6.5个月,1年生存率52.8%,生活质量改善69.4%.化疗不良反应主要为骨髓抑制及周围神经毒性,发生率分别为69.4%、55.6%,多为Ⅰ~Ⅱ度.结论：多西他赛联合FOLFOX6治疗晚期胃癌疗效好,不良反应可耐受.